Vera Therapeutics (NASDAQ:VERA) Given “Buy” Rating at HC Wainwright
HC Wainwright reissued their buy rating on shares of Vera Therapeutics (NASDAQ:VERA – Free Report) in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has a $25.00 price objective on the stock. Several other research analysts have also recently issued reports on VERA. Raymond James started coverage on Vera Therapeutics in […]
More Stories
US Foreclosure Filings Jump 5 Percent in February
By Naveen Athrappully The number of foreclosure filings in the United States rose by 5 percent in February over the...
Sugary Drinks Linked to an Increase in Oral Cancer Risk Among Women: New Research
By George Citroner Women who indulge in just one sugar-sweetened beverage a day are nearly five times more likely to...
Canada’s Ambassador, Ontario Rep Say They Have Clearer Idea of What Trump Is After Following DC Meeting
By Isaac Teo Canadian representatives say they now have a clearer understanding of what U.S. President Donald Trump is pursuing...
More Than 250 Tren de Aragua Gang Members Deported to El Salvador Prison: Rubio
By Jacob Burg Secretary of State Marco Rubio said on March 16 that the Trump administration had sent more than...
ICE Arrests 214 Criminal Illegal Immigrants in Virginia
By Naveen Athrappully An enforcement operation in northern Virginia has led to the arrests of 214 criminal illegal immigrants, including...
The AES Co. (NYSE:AES) Shares Sold by PNC Financial Services Group Inc.
PNC Financial Services Group Inc. reduced its position in shares of The AES Co. (NYSE:AES – Free Report) by 19.9%...